Announcements & Media Coverage

Hemogenyx Pharmaceuticals plc (“Hemogenyx Pharmaceuticals” or the “Company”)   U.S. Approval and Issuance of Monoclonal Antibody Patent   Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases (“Company”), is pleased to announce that a further patent application entitled MONOCLONAL ANTIBODIES TO HUMAN FLT3/FLK2 RECEPTOR PROTEIN has been approved and...